More Investors. More Opportunities. More Momentum.

August 11, 2026August 11, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Investor interest in RESI Boston is building quickly as the launch of the RESI partnering platform approaches on Monday, August 17. With partnering just days away, investor registrations are expected to accelerate further as firms prepare to identify companies and begin scheduling one-on-one meetings.

In five days of investor registration, more than 30 investor firms signed up to participate, reinforcing RESI’s position as one of the premier partnering events for early-stage life science companies seeking capital and strategic partnerships.

Recently Confirmed Investors (Last 5 Days)

Explore the full RESI Boston investor list here.

These new registrations join a growing community of investors from across venture capital, corporate venture, family offices, angel groups, foundations, and strategic investment organizations, creating even more opportunities for meaningful one-on-one meetings.

🏷️ Save $300 on RESI Boston Registration

Secure your pass before Early Bird rates end this Friday, August 14th to get full access to investor partnering!

Already, more than 200 investors representing over 150 global investor firms have registered for RESI Boston, with additional investors continuing to join each week.

As the investor roster continues to grow, so do the opportunities to connect with the partners who can help move your company forward.

Register now to join one of the industry’s most active life science partnering events. Early Bird pricing ends Friday, August 14, giving attendees one last opportunity to save $300 before standard rates take effect.

Partnering Launches August 17 for RESI Boston September 2026

August 11, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

RESI Boston September 2026 brings together one of the largest gatherings of early-stage life science investors, pharmaceutical and medtech business development professionals, strategic partners, and innovators during Biotech Week Boston. With two days of in-person networking, educational panels, company presentations, the Innovator’s Pitch Challenge, an active exhibit hall, and dedicated one-on-one partnering, RESI is designed to help emerging life science companies build the relationships that drive fundraising, licensing, strategic partnerships, and commercialization.

One of the event’s most valuable features launches Monday, August 17: the RESI partnering platform.

Beginning August 17, registered attendees can start scheduling one-on-one meetings with investors, pharmaceutical business development teams, strategic partners, and service providers well in advance of the conference.

The RESI series continues to be one of the world’s largest early-stage life science partnering events, bringing together hundreds of active investors and strategic partners focused on biotechnology, AI, medical devices, diagnostics, digital health, and life science tools. Whether attending in person or virtually, participants can use Life Science Nation’s (LSN) proprietary partnering platform to identify organizations that align with their technology, stage of development, therapeutic focus, and fundraising objectives.

Launching your partnering outreach early is one of the best ways to maximize your RESI experience. Companies that complete their profiles and begin requesting meetings as soon as partnering opens gain greater visibility and have more opportunities to secure valuable conversations before schedules begin to fill.

To help attendees make the most of the partnering platform, Life Science Nation will host a complimentary RESI Boston Partnering Tutorial webinar on Tuesday, August 18, at 9:00 AM MT. During this interactive session, LSN staff will demonstrate how to:

Build a compelling partnering profile
Identify investors and strategic partners that best fit your company
Develop an outreach strategy that increases meeting acceptance
Manage meeting requests and follow up effectively
Leverage the partnering platform and conference resources to maximize your RESI experience

🎓 Free Webinar: RESI Partnering Tutorial

Learn outreach strategies to maximize your 1-on-1 investor meetings. Tuesday, Aug 18 @ 11:00 AM ET

Whether you are attending RESI for the first time or are a returning participant, this tutorial offers practical strategies to help you secure more meaningful meetings and maximize your return on investment.

Register now to secure your $300 Early Bird savings before August 14, complete your partnering profile, begin requesting meetings when the platform opens on August 17, and join the complimentary Partnering Tutorial on August 18 to position your company for a productive and successful RESI Boston September 2026.

🏷️ Save $300 on RESI Boston Registration

Secure your pass before Early Bird rates end this Friday, August 14th to get full access to investor partnering!

Hot Investor Mandate: Asia-Based Life Science Venture Capital Investing in Pre-A to Series B Therapeutics, Devices, and Diagnostics Companies Across Global Markets

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This investment firm is headquartered in Asia with offices in North America and focuses on early-stage investments in life sciences and healthcare. The firm typically participates in pre-Series A to Series B financing rounds, with initial investment sizes ranging from several hundred thousand dollars to several million dollars and the potential for follow-on investments. The firm seeks opportunities primarily in Europe, as well as North America and the United Kingdom. The firm is open to both leading and co-investing in financing rounds.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is open to evaluating digital health and AI-related companies but has limited investment activity in these areas to date. The firm takes an opportunistic approach across subsectors and indications, with areas of interest including immunology, immuno-oncology, central nervous system disorders, and kidney-related diseases.

For therapeutics, the firm considers opportunities from Phase I and beyond, particularly companies with proof-of-concept data or clinical validation supporting their technologies. For medical devices and diagnostics, the firm generally seeks more mature companies with products or prototypes in development, along with clear regulatory approval strategies.

The firm does not have specific requirements for management teams but prefers to work with founding teams that have prior entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: US-Based Family Office Investing in Therapeutics, Medical Devices, and Diagnostics Companies with Strong Social Impact Focus Addressing Underserved Medical Needs

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This single-family office represents private family interests in the United States. The firm is flexible in terms of investment size but generally looks to invest at least several hundred thousand dollars per round, depending on round size and anticipated capital requirements. The firm prefers Series A and later-stage companies, while pre-Series A opportunities are considered depending on technology maturity. Currently, the firm invests primarily in companies based in North America.

The firm seeks breakthrough technologies with a strong social impact focus in the therapeutics, medical devices, and diagnostics sectors that address underserved medical needs or provide innovative and disruptive approaches to existing medical procedures and treatments. Areas of particular interest include optical and sound-based technologies, devices that reduce reliance on drug-based treatments, orthopedics, gene and nucleic acid-based therapies, immuno-oncology, and technologies addressing sensory loss.

The firm reviews co-investment opportunities in private companies and, on an opportunistic basis, may consider investments in micro- and small-cap public companies as a direct investor. The firm seeks companies that have completed seed financing and have reached key intellectual property milestones, including allowance of claims by relevant patent authorities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: US-Based Healthcare VC Focused on Medical Technologies and Digital Health Solutions, Investing Across Early- and Late-Stage Opportunities

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This venture capital firm was founded in the mid-2000s and manages approximately $100 million in assets across multiple funds. The firm makes equity investments ranging from several hundred thousand dollars to several million dollars, with additional capital reserved for follow-on rounds. The firm invests in companies located throughout North America and Europe and plans to make several new investments over the next year. The firm invests in both early-stage companies and later-stage commercial growth opportunities.

The firm focuses on companies developing medical devices, diagnostics, and healthcare IT products, with an emphasis on capital-efficient technologies that can reach the market quickly and reduce the cost of delivering quality healthcare. The firm is open to a broad range of subsectors and indications within medical technology, with particular interest in technologies related to cardiovascular health and neurological applications.

The firm seeks companies with skilled and experienced management teams. The firm generally looks to take board seats in portfolio companies after investment and plays an active role in supporting company growth and strategic decisions.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: CVC Arm of Global Pharmaceutical Company Focuses on Early-Stage Therapeutics and Technologies Enhancing Drug Discovery and Pharmaceutical R&D

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This corporate venture fund was established in 2023 to invest in innovative life sciences companies developing technologies strategically aligned with its parent pharmaceutical company’s long-term research and development priorities. Headquartered in the United States, the fund manages evergreen capital and invests globally, with a primary focus on companies based in North America, Europe, and Asia. The fund typically makes initial investments of several million dollars and has the capacity to provide additional follow-on capital over the life of a portfolio company. The fund seeks to support breakthrough scientific innovation while building long-term strategic relationships with emerging biotechnology companies through minority equity investments.

The fund focuses on early-stage therapeutics, enabling platform technologies, and digital technologies that can enhance drug discovery and pharmaceutical R&D. Areas of particular interest include advanced therapeutic modalities, targeted drug discovery approaches, next-generation biologics, RNA-based technologies, and platform technologies capable of generating multiple therapeutic programs across diverse disease areas. Within digital technologies, the fund primarily seeks artificial intelligence, machine learning, computational biology, and data science applications that improve target identification, drug design, lead optimization, and other aspects of drug discovery and development. The fund focuses primarily on preclinical and early clinical-stage opportunities and does not invest in medical devices, diagnostics, healthcare services, or patient-centric digital health applications.

The fund invests in privately held biotechnology companies and does not maintain rigid management team requirements. The fund typically participates as a minority investor alongside other life sciences investors and generally does not lead financing rounds or require board representation. Instead, the fund seeks collaborative relationships with innovative companies whose technologies have strategic relevance to its research organization while allowing portfolio companies to remain operationally independent.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Establish Your Innovation Hub at RESI JPM 2027

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

Every January, JPM Healthcare Week transforms San Francisco into the global center of the life science industry, bringing together investors, pharmaceutical executives, biotech leaders, and innovators from around the world. For organizations looking to showcase their regional ecosystem, portfolio companies, or innovation network, RESI JPM 2027 offers a unique opportunity to establish a visible and strategic presence during one of the industry’s most influential weeks.

Located within the San Francisco Marriott Marquis, RESI JPM is the premier partnering conference dedicated to early-stage life science companies. The event connects startups with active investors, strategic partners, and business development professionals through curated partnering meetings, educational programming, and networking opportunities.

Life Science Nation invites regional organizations, innovation hubs, accelerators, and industry partners to create their own branded Innovation Hub alongside RESI JPM. These flexible hosting opportunities allow organizations to provide a central gathering place for their ecosystem while taking advantage of the high concentration of attendees already participating in RESI and JPM Healthcare Week.

RESI JPM 2027 Venue: Salons 9–15 (Yerba Buena Ballroom, Lower B2 Level) with total space exceeding 17,000 sq ft.

Organizations can kick off the week with a private networking reception on Sunday, welcoming investors, founders, corporate partners, and key stakeholders before the week’s meetings begin. During RESI JPM on Monday and Tuesday, dedicated salon spaces adjacent to the conference offer an ideal location for hosting meetings, showcasing portfolio companies, conducting presentations, and serving as a home base for delegates throughout the event.

Tech/Innovation hubs also benefit from prominent branding within the RESI environment and the opportunity for their startup cohorts to engage directly in RESI’s partnering platform, creating additional exposure and meeting opportunities with investors and strategic partners.

Whether representing a regional life science cluster, government agency, incubator, accelerator, or investment organization, establishing an Innovation Hub at RESI JPM positions your organization at the center of the world’s largest life science partnering week while providing lasting value for your innovation ecosystem.

To learn more about creating an Innovation Hub at RESI JPM 2027, contact Life Science Nation at salescore@lifesciencenation.com.